Blast off! Mesoblast share price surging 60%

Mesoblast shares are skyrocketing today.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price shot out of the gates on Tuesday, opening at 80 cents per share and rising to an intraday peak of 88.5 cents within the first two hours of trading.

The intraday high represents a 59.45% gain over the closing price of 55.5 cents last Thursday, prior to the market shutdown for the Easter long weekend.

At the time of writing, the Mesoblast share price has settled back to 87 cents per share.

What's the news from Mesoblast today?

The only news from the biotech company today is a non-price-sensitive announcement relating to a change in substantial holding.

That's for United States investor Gregory George and G to the Fourth Investments.

The notice advised a collective stake increase from 10.23% to 11.99% last Thursday.

There's no other news today.

However, Mesoblast did have a big announcement last week that sent its share price soaring.

Let's recap.

What's pushing the Mesoblast share price higher?

Mesoblast requested a pause in trading last Tuesday morning before releasing some big news.

The company announced that the US Food and Drug Administration (FDA) had informed it that after reviewing the clinical data from its Phase 3 study, there appeared to be sufficient evidence to support Mesoblast's submission for remestemcel-L to treat kids with steroid-refractory acute graft versus host disease (SR-aGVHD).

Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease.

CEO Silviu Itescu said the company would now refile its Biologics License Application (BLA). This will happen in the June quarter after the company addresses outstanding product characterisation matters.

Silviu said:

The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SR-aGVHD.

What is remestemcel-L?

This is the drug that Mesoblast has been trying to get approved for the past three-and-a-half years.

There was much excitement in mid-2020 while Mesoblast was awaiting the FDA's first decision on its flagship drug, also known as Ryoncil.

This can be seen in the Meosblast share price chart below.

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Remestemcel-L has FDA Fast Track designation, a process to facilitate the development and speedy
review of therapies for serious conditions that fill unmet medical needs.

It also has Priority Review designation, which is given to drugs that treat a serious condition and provide a significant improvement in safety or effectiveness over existing treatments.

Survival outcomes have not improved for 20 years for children or adults with the most severe forms of SR-aGVHD.

As you can see, the Mesoblast share price was trading above $5 per share back in those days.

The market was shocked when the FDA knocked back the application in October 2020.

Mesoblast worked with the FDA for two years to address the issues. It resubmitted its Biologics License Application (BLA) resubmission for remestemcel-L in the treatment of children in March 2023.

But the FDA knocked it back again in August. The Mesoblast share price spiralled down almost 60% after the FDA said it needed more data to support marketing approval for remestemcel-L for kids.

Mesoblast then sat down with the FDA in what is called a Type A meeting.

The FDA advised the company that the key remaining issue for pediatric approval was providing further evidence that the potency assay will assure the consistent efficacy of the commercial product.

Mesoblast later provided the FDA with new data from a second potency assay.

The company said:

The new data show that the RYONCIL product made with the current manufacturing process that
has undergone successful inspection by FDA, demonstrates greater potency than the earlier
generation product, providing context to its greater impact on survival.

Mesoblast has been waiting for the FDA to respond to the new data ever since.

Mesoblast share price snapshot

The Mesoblast share price is down 13.3% over the past 12 months.

However, in the year to date, it is up 174%.

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »